The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04647526
Recruitment Status : Active, not recruiting
First Posted : December 1, 2020
Last Update Posted : April 19, 2024
Information provided by (Responsible Party):
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company